Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCB-219
- Development stage
- Phase 1
- Lead developer
- Clover Biopharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
**SCB-219** is an investigational biologic thrombopoietin receptor agonist designed as a mimetic bispecific Fc-fusion protein derived from Chinese hamster ovary cells using Clover Biopharmaceuticals' Fc-fusion platform. It targets the thrombopoietin receptor to stimulate platelet production and is being developed by Clover Biopharmaceuticals for chemotherapy-induced thrombocytopenia and broader cancer treatment-induced thrombocytopenia in patients with cancer. Publicly described early clinical data indicate a favorable preliminary safety, pharmacokinetic, and platelet-response profile, with an extended serum half-life that may support dosing intervals of at least two weeks, differentiating it from shorter-acting daily or weekly thrombopoietic agents.
- Other names
- SCB-219MSCB219MSCB 219M
02
Targets
TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on SCB-219.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCB-219.